Literature DB >> 20922143

Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy.

Joseph Menczer1, Angela Chetrit, Siegal Sadetzki.   

Abstract

OBJECTIVE: Possible reasons for hysterectomy in the initial surgical management of advanced invasive epithelial ovarian carcinoma (EOC) might be a high frequency of uterine involvement and its impact on survival. The aim of the present study was to describe the frequency of uterine involvement and its association with survival in an unselected population of EOC patients who underwent hysterectomy.
METHODS: All incident cases of EOC diagnosed in Israeli Jewish women between March 1994 to June 1999, were identified within the framework of a nationwide case-control epidemiological study. The target population of the present report includes all stage II-IV EOC patients who had a uterus at the time of diagnosis. Of the 822 such patients, 695 fulfilled the inclusion criterion. Excluded were 141 patients for various reasons. The present analysis is based on the remaining 554 patients.
RESULTS: Uterine involvement was present in 291 (52.5%) of the patients and it was macroscopic in only 78 (14.1%). The serosa was the most common site of isolated metastases. Multivariate analysis showed that advanced stage significantly increased the risk for uterine involvement. The overall median survival with any uterine involvement was significantly lower compared to those with no involvement (38.9 months vs. 58.0 months; p<0.001).
CONCLUSION: There is an association between uterine involvement, whether macro- or microscopic, and lower survival even after hysterectomy although residual tumor could not be included in the analysis. Further studies are required to establish whether uterine involvement itself is an unfavorable risk factor or merely a marker of other unfavorable prognostic factors.

Entities:  

Keywords:  Epithelial ovarian carcinoma; Survival; Uterine involvement

Year:  2010        PMID: 20922143      PMCID: PMC2948228          DOI: 10.3802/jgo.2010.21.3.191

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  27 in total

Review 1.  Cytoreductive surgery in the treatment of advanced ovarian carcinoma. Some controversial aspects.

Authors:  J Menczer
Journal:  Eur J Gynaecol Oncol       Date:  1992       Impact factor: 0.196

2.  Significance of a positive Papanicolaou smear in a well screened population.

Authors:  D S Lyon; P F Kaminski; J B Wheelock
Journal:  South Med J       Date:  1989-02       Impact factor: 0.954

3.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Authors:  B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

Review 4.  Primary surgery for ovarian cancer.

Authors:  C Tropé; J Kaern
Journal:  Eur J Surg Oncol       Date:  2006-05-04       Impact factor: 4.424

Review 5.  Operative management of primary epithelial ovarian cancer.

Authors:  Mario M Leitao; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

6.  Metastases to the female genital tract. Analysis of 325 cases.

Authors:  M T Mazur; S Hsueh; D J Gersell
Journal:  Cancer       Date:  1984-05-01       Impact factor: 6.860

7.  Ovarian carcinoma presenting as a cervical metastasis.

Authors:  B C McComas; J B Farnum; R C Donaldson
Journal:  Obstet Gynecol       Date:  1984-04       Impact factor: 7.661

8.  Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

Authors:  R W Hunter; N D Alexander; W P Soutter
Journal:  Am J Obstet Gynecol       Date:  1992-02       Impact factor: 8.661

9.  Cervical metastases in advanced ovarian malignancies.

Authors:  H M Tarraza; H G Muntz; M De Cain; M A Jones
Journal:  Eur J Gynaecol Oncol       Date:  1993       Impact factor: 0.196

10.  Metastatic patterns in adenocarcinoma.

Authors:  Kenneth R Hess; Gauri R Varadhachary; Sarah H Taylor; Wei Wei; Martin N Raber; Renato Lenzi; James L Abbruzzese
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

View more
  3 in total

1.  CAP1 is overexpressed in human epithelial ovarian cancer and promotes cell proliferation.

Authors:  Minhui Hua; Sujuan Yan; Yan Deng; Qinghua Xi; Rong Liu; Shuyun Yang; Jian Liu; Chunhui Tang; Yingying Wang; Jianxin Zhong
Journal:  Int J Mol Med       Date:  2015-02-04       Impact factor: 4.101

2.  Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.

Authors:  Courtney D Bailey; Rebecca Previs; Bryan M Fellman; Tarrik Zaid; Marilyn Huang; Alaina Brown; Ahmed Enbaya; Nyla Balakrishnan; Russell R Broaddus; Diane C Bodurka; Pamela Soliman; Nicole D Fleming; Alpa Nick; Anil K Sood; Shannon Neville Westin
Journal:  Int J Gynecol Cancer       Date:  2020-10-29       Impact factor: 3.437

3.  Uterine involvement in epithelial ovarian cancer and its risk factors.

Authors:  Narges Zamani; Azam Sadat Mousavi; Setare Akhavan; Shahrzad Sheikhhasani; Somayeh Nikfar; Elham Feizabad; Elahe Rezayof; Mitra Modares Gilani
Journal:  J Ovarian Res       Date:  2021-12-07       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.